$LRMRJun 26, 2026, 8:07 PMAI processed
Larimar (LRMR) schedules June 29 webcast with nomlabofusp regulatory update and long-term study data
AI Summary
Larimar Therapeutics (LRMR) will host an investor webcast on June 29, 2026 to provide a regulatory update and present data from its ongoing long-term open-label study of nomlabofusp for Friedreich's ataxia. The event could move expectations for BLA timing and give longer-term safety/efficacy signals, but the announcement gives no specific results, sample sizes, or firm submission dates.
Positives
- Webcast scheduled for June 29 to deliver a regulatory update and long-term open-label study data for nomlabofusp
- Nomlabofusp is the company's lead program targeting adults and children with Friedreich’s ataxia
- Company references regulatory strategy including potential BLA timelines and Breakthrough Therapy-related expectations
Negatives
- No data, sample sizes, endpoints, or specific timeline details were disclosed in this announcement
- Data come from an ongoing open-label study, which is non-randomized and may be preliminary
- Forward-looking statements highlight material regulatory and development risks that could change timing or outcomes